Who Is Buying Moderna? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Moderna (MRNA) based on latest 13F filings. 7 funds buying, 3 new positions opened.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Moderna? Hedge Fund Activity in 2026
Moderna, the mRNA pioneer that became a household name during the COVID-19 pandemic, is now navigating one of the most consequential chapters in its corporate history. Having built a massive cash war chest from COVID vaccine sales, the company is aggressively reinvesting into its next-generation pipeline — including RSV vaccines, individualized cancer therapies, and combination respiratory shots. The stock has been volatile, oscillating between pandemic-era hype and post-pandemic skepticism, but the latest institutional filings suggest that smart money is increasingly placing bets on Moderna's future beyond COVID.
The most recent 13F filings paint a decidedly bullish picture: 7 out of 15 tracked funds are buying or increasing their Moderna positions, with three entirely new positions opened during the quarter. This is a significant shift in institutional sentiment for a stock that many had written off.
Quick Answer
Across the funds we read directly from SEC filings, the largest Moderna position in the Q2 2026 13Fs (period ending 30 June 2026) is Millennium Management at $31M (438,615 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Millennium Management, where Moderna is 0.0% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Moderna Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 7 |
| Funds Selling | 4 |
| Funds Holding | 4 |
| Active Funds Tracked | 15 |
A 7-to-4 buy-sell ratio represents a moderately bullish tilt. What makes this particularly noteworthy is the three brand-new positions — Renaissance Technologies, Coatue Management, and Appaloosa Management all initiated fresh stakes. When multiple sophisticated quant and fundamental shops simultaneously decide to enter a name, it's worth paying attention.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho holds Moderna, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Millennium Management | $31M | 438,615 | 0.0% of $142.92B |
| Citadel Advisors | $21M | 294,496 | 0.0% of $171.84B |
| Bridgewater Associates | $807k | 11,527 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Moderna that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Bridgewater Associates | 74,822 | 11,527 | -85% |
| Millennium Management | 1,019,208 | 438,615 | -57% |
| Citadel Advisors | 489,770 | 294,496 | -40% |
A fund absent from this table reported no Moderna position in either quarter.
Related Articles
- Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
- Who Is Buying Regeneron? Hedge Fund Activity in 2026
- Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026
FAQ
Why are funds revisiting Moderna after the post-COVID drawdown?
The bullish case has shifted from COVID boosters to the broader mRNA platform — RSV vaccines, flu-COVID combinations, and personalized cancer vaccines partnered with Merck. Institutional buyers appear to be positioning ahead of pipeline catalysts rather than reacting to legacy COVID revenue trends.
What's notable about Renaissance, Coatue, and Appaloosa all opening new positions?
Three sophisticated funds with very different methodologies — quantitative, platform-technology growth, and contrarian value — initiating in the same quarter is statistically unusual. That convergence across investment philosophies is one of the stronger signals visible in the 13F data, though it doesn't guarantee outcomes.
How significant is Moderna's oncology pipeline for the investment thesis?
The Merck-partnered individualized cancer vaccine (mRNA-4157) is widely seen as the highest-value asset beyond respiratory infectious disease. If Phase 3 melanoma data reads out positively, it would validate mRNA as an oncology platform — a re-rating event that several institutional buyers appear to be underwriting.
Is the selling from State Street and Two Sigma a concern?
The reductions look more tactical than conviction-driven. State Street still holds over $805 million and Two Sigma over $361 million, so neither is exiting — the trims read as portfolio maintenance, index rebalancing, and short-horizon quant repositioning rather than a fundamental view change.
What are the main risks institutional buyers are absorbing?
Moderna burns substantial cash funding pipeline expansion, and the platform still needs commercial wins beyond COVID to justify current valuation. Clinical setbacks, regulatory delays, or competitive mRNA programs could quickly reverse the improving institutional sentiment captured in these filings.